- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Vor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | 778 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| 13.05. | Vor Biopharma reports Q1 results | 3 | Seeking Alpha | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade | 5 | Zacks | ||
| 04.05. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 15.04. | H.C. Wainwright senkt Kursziel für Vor Biopharma auf 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 15.04. | H.C. Wainwright lowers Vor Biopharma price target to $31 | 1 | Investing.com | ||
| 08.04. | Stifel reiterates Vor Biopharma stock rating on drug potential | 1 | Investing.com | ||
| 08.04. | Stifel bekräftigt Kaufempfehlung für Vor Biopharma wegen Medikamentenpotenzial | 1 | Investing.com Deutsch | ||
| 01.04. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 30.03. | Stifel cuts Vor Biopharma stock price target on financing assumptions | 2 | Investing.com | ||
| 30.03. | Stifel senkt Kursziel für Vor Biopharma aufgrund neuer Finanzierungsannahmen | 2 | Investing.com Deutsch | ||
| 30.03. | Vor Biopharma reports Q4 results | 2 | Seeking Alpha | ||
| 30.03. | Vor Bio doses first patient in phase 3 Sjögren's disease trial | 1 | Investing.com | ||
| 30.03. | Vor Biopharma: Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease | 330 | GlobeNewswire (Europe) | BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first... ► Artikel lesen | |
| 30.03. | Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 348 | GlobeNewswire (Europe) | First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept... ► Artikel lesen | |
| 30.03. | Vor Biopharma Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Vor Biopharma Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 29.03. | Jefferies startet Vor Biopharma mit Kaufempfehlung nach strategischer Neuausrichtung | 6 | Investing.com Deutsch |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| EDITAS MEDICINE | 2,340 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GERON | 1,039 | +1,86 % | Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights | Achieved $51.8 million in RYTELO- (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Appointment of Davidson & Company as Its New Auditor | Toronto, Ontario--(Newsfile Corp. - May 22, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), is pleased to announce the appointment of Davidson... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,705 | -0,53 % | FATE THERAPEUTICS INC - 8-K, Current Report | ||
| TRINITY BIOTECH | 0,668 | 0,00 % | TRINITY BIOTECH PLC - 6-K, Report of foreign issuer | ||
| ARCTURUS THERAPEUTICS | 7,305 | +0,07 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| OVID THERAPEUTICS | 2,120 | +1,92 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors | NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant... ► Artikel lesen | |
| CERVOMED | 2,520 | +4,13 % | CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing Presented new analyses at... ► Artikel lesen | |
| EQUILLIUM | 2,640 | +2,72 % | Equillium, Inc.: Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| CABALETTA BIO | 3,235 | -0,46 % | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress | 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,640 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 20,070 | +0,40 % | Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio? | ||
| THX PHARMA | 3,105 | 0,00 % | THERANEXUS: THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update | Lyon, France - April 28, 2026 - 7:00 p.m. CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces its... ► Artikel lesen | |
| LONGEVERON | 0,741 | +1,51 % | Longeveron Inc. - 8-K, Current Report |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 13,160 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.